Accessibility: Skip TopNav
Figure 3. 1st MSA patient on nasal foralumab
Marked reduction in basal ganglia uptake following nasal foralumab
Format
PNG
Quelle:
Tiziana Life Sciences Ltd.
Downloads
Originalgröße
Groß
Mittel
Klein